Single-cell RNA-seq analysis of immune microenvironment changes in pancreatic cancer following combined EZH2 and KRAS inhibition
Our study demonstrated that combined treatment with the EZH2 inhibitor tazemetostat and the KRAS inhibitor RMC-6236 significantly suppressed the growth of both subcutaneous and orthotopic tumors. To investigate changes in the tumor microenvironment following combined EZH2 and KRAS inhibition in pancreatic cancer, mice bearing subcutaneous KPC tumors were treated with vehicle, RMC-6236 alone, or RMC-6236 in combination with tazemetostat. CD45? cells were isolated and subjected to 10× Genomics single-cell RNA sequencing. Overall design: Mice bearing KPC tumor were treatment with vehicle, RMC-6236 or its combination with tazemetostat for 2 days, and then intratumoral CD45+ cells were isolated using BD FACSAriaIII for sc-RNAseq..